A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
What is the purpose of this trial?
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Trial withCybrexa Therapeutics, Inc.
- Start Date06/13/2022
- End Date01/01/2024
- Last Updated06/14/2022
- Study HIC#2000030687